A Real-World Study of the Effect of rhG-CSF on Clinical Efficacy and Flow Cytometry MRD after Initial Induction Therapy for Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2022.04.008
- Author:
Mei ZHOU
1
;
Fu-Run AN
1
;
Qing ZHANG
1
;
Yi DONG
1
;
Hui QIN
1
;
Zhi-Min ZHAI
1
;
Qian-Shan TAO
2
Author Information
1. Department of Hematology, The Second Hospital of Anhui Medical University, Hefei 230601, Anhui Province, China.
2. Department of Hematology, The Second Hospital of Anhui Medical University, Hefei 230601, Anhui Province, China. E-mail: ahmutqs@126.com.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
complete remission;
fever;
minimal residual disease;
recombinant human granulocyte colony stimulating factor
- MeSH:
Flow Cytometry;
Granulocyte Colony-Stimulating Factor/therapeutic use*;
Humans;
Induction Chemotherapy/adverse effects*;
Leukemia, Myeloid, Acute/therapy*;
Neoplasm, Residual/etiology*;
Neutropenia;
Recombinant Proteins/therapeutic use*;
Retrospective Studies;
Treatment Outcome
- From:
Journal of Experimental Hematology
2022;30(4):1022-1027
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effect of recombinant human granulocyte colony stimulating factor (rhG-CSF) on the clinical efficacy and flow cytometry (FCM) minimal residual disease (MRD) of patients with acute myeloid leukemia (AML) after initial induction therapy in the real world.
METHODS:The clinical data of 44 AML patients who were diagnosed for the first time in the Department of Hematology, The Second Hospital of Anhui Medical University, and received the initial induction therapy were retrospectively analyzed. According to whether rhG-CSF was used after treatment, these patients were divided into control group and therapy group. The complete remission (CR) rate, duration of neutropenia, incidence of infection, duration of fever, cost of antibiotics drugs, length of hospital stay, FCM MRD, and relapse-free survival (RFS) time were compared between the two groups.
RESULTS:The CR rate in the control group was 60%, and 74% in the therapy group (P=0.3429). The duration of neutropenia was (21.28±7.91) days in the control group and (14.79±3.07) days in the therapy group (P=0.0016). The duration of fever was (12.80±7.31) days in the control group and (9.11±7.48) days in the therapy group (P=0.0136). While, there were no statistically significant differences between the two groups in the incidence of infection, cost of antibacterial drugs, length of hospital stay and RFS time (all P>0.05). In addition, it is particularly noteworthy that among the patients who finally obtained CR in the therapy group, 66% of them had myeloid precursor cells detected by peripheral blood FCM (accounting for 2.25%±0.99%) at the time of the first release of neutropenia, which was easy to be misdiagnosed as MRD positive.
CONCLUSION:rhG-CSF not only don't affect the clinical remission rate after the initial induction treatment of AML, but also significantly shortens the time of duration of neutropenia and fever, however, it may affect the analysis of peripheral blood FCM MRD detection results when the neutropenia is released for the first time.
